Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. DBV Technologies S.A.
  6. Summary
    DBV   FR0010417345

DBV TECHNOLOGIES S.A.

(DBV)
  Report
Real-time Quote. Real-time Euronext Paris - 01/21 06:02:46 am
2.904 EUR   +1.36%
01/20European ADRs Move Lower in Thursday Trading
MT
01/19European ADRs Move Higher in Wednesday Trading
MT
01/07DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
2.995(c) 2.972(c) 2.859(c) 2.865(c) 2.904 Last
159 629 159 610 504 893 253 132 75 281 Volume
+0.47% -0.77% -3.80% +0.21% +1.36% Change
More quotes
Estimated financial data (e)
Sales 2021 4,21 M 4,76 M 4,76 M
Net income 2021 -96,0 M -109 M -109 M
Net cash position 2021 83,2 M 94,3 M 94,3 M
P/E ratio 2021 -1,70x
Yield 2021 -
Sales 2022 5,02 M 5,68 M 5,68 M
Net income 2022 -94,9 M -107 M -107 M
Net cash position 2022 38,9 M 44,0 M 44,0 M
P/E ratio 2022 -2,20x
Yield 2022 -
Capitalization 158 M 179 M 179 M
EV / Sales 2021 17,7x
EV / Sales 2022 23,7x
Nbr of Employees 92
Free-Float 91,5%
More Financials
Company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to... 
Sector
Pharmaceuticals
Calendar
01/21Presentation
More about the company
Ratings of DBV Technologies S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about DBV TECHNOLOGIES S.A.
01/20European ADRs Move Lower in Thursday Trading
MT
01/19European ADRs Move Higher in Wednesday Trading
MT
01/07DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
AQ
01/05European ADRs Move Higher in Wednesday Trading
MT
01/03European ADRs Move Higher in Monday Trading
MT
2021DBV TECHNOLOGIES S.A. : Monthly statement on outstanding equity shares and voting rights
CO
2021European ADRs Nudge Lower in Tuesday Trading
MT
2021European ADRs Move Higher in Thursday Trading
MT
2021DBV Technologies Stock Rallies 14% After Posting Losses Yesterday Following EU Applicat..
MT
2021European ADRs Rising Wednesday
MT
2021DBV Technologies Withdraws EU Marketing Application for Viaskin Peanut Allergy Patch, P..
MT
2021European ADRs Move Higher in Tuesday Trading
MT
2021JMP Securities Adjusts Price Target on DBV Technologies to $5 From $8, Maintains Market..
MT
2021HC Wainwright Adjusts DBV Technologies' Price Target to $10 From $14, Keeps Buy Rating
MT
2021DBV Technologies Provides Update on Investigational Viaskinâ„¢ Peanut
AQ
More news
News in other languages on DBV TECHNOLOGIES S.A.
01/20Les ADR européens en baisse jeudi
01/19Les ADR européens sont en hausse mercredi
01/19BOLSA DE MADRID : Una boda y cuatro funerales
01/19Un mariage et quatre enterrements
01/19AVIS D'ANALYSTES DU JOUR : Safran, Veolia, Schneider, EDF, Lonza, Ryanair, Adecco, Alfen, ..
More news
Analyst Recommendations on DBV TECHNOLOGIES S.A.
More recommendations
Chart DBV TECHNOLOGIES S.A.
Duration : Period :
DBV Technologies S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DBV TECHNOLOGIES S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 2,87 €
Average target price 7,58 €
Spread / Average Target 164%
EPS Revisions
Managers and Directors
Daniel Tassé Chief Executive Officer & Executive Director
Sébastien Robitaille Chief Financial Officer
Michel de Rosen Non-Executive Chairman
Pharis Mohideen Chief Medical Officer
Pascal Wotling Chief Technical Operations Officer
Sector and Competitors